歡迎光臨源葉生物,登錄 | 注冊 |
當(dāng)前位置: 首頁 > 小分子抑制劑 > Immunology/Inflammation > Cenicriviroc

瀏覽歷史

S85553

Cenicriviroc

源葉(MedMol) 97%
  • 英文名:
  • Cenicriviroc
  • 別名:
  • CAS號:
  • 497223-25-3
  • 分子式:
  • C41H52N4O4S
  • 分子量:
  • 696.94
  • 核磁/質(zhì)譜:
品牌貨號產(chǎn)品規(guī)格價格(RMB) 庫存(上海) 北京 武漢 南京 數(shù)量計量單位 加入購物車...
源葉(MedMol) S85553-1mg 97% ¥250.00元 2 - - - EA 加入購物車
源葉(MedMol) S85553-5mg 97% ¥1040.00元 6 - - - EA 加入購物車
源葉(MedMol) S85553-10mg 97% ¥1530.00元 5 - - - EA 加入購物車
源葉(MedMol) S85553-50mg 97% ¥4080.00元 5 - - - EA 加入購物車
大包裝詢價

提交您的電話號碼并同意《個人信息授權(quán)與保護(hù)申明》,到貨后將短信提示。
提交

產(chǎn)品介紹

參考文獻(xiàn)

質(zhì)檢證書(COA)

摩爾濃度計算器

相關(guān)產(chǎn)品

  • 提示:詳情請下載說明書。
  • 產(chǎn)品描述:

    Cenicriviroc (CVC, TAK-652, TBR-652) 是一種有效的、口服活性的 CC chemokine receptor 2 (CCR2) 和 CCR5 的雙效抑制劑。Cenicriviroc 還可抑制 HIV-1 和 HIV-2 并具有有效的抗炎和抗感染活性

  • 靶點(diǎn): CCR2;CCR5;HIV-1;HIV-2;HIVProtease;CCR
  • 體內(nèi)研究:
    Cenicriviroc significantly reduces monocyte/macrophage recruitment in vivo at doses >= 20 mg/kg/day (p < 0.05). At these doses, Cenicriviroc shows antifibrotic effects, with significant reductions in collagen deposition (p < 0.05), and collagen type 1 protein and mRNA expression across the three animal models of fibrosis. In the NASH model, Cenicriviroc significantly reduces the nonalcoholic fatty liver disease activity score (p < 0.05 vs. controls). Cenicriviroc treatment has no notable effect on body or liver/kidney weight.
  • 細(xì)胞實(shí)驗(yàn): Cell lines: activated macrophages Concentrations: 1 μM Incubation Time: 2 h Method: TG is injected intraperitoneally into male C57BL/6 mice and activated macrophages are collected 48 hours later by peritoneal lavage. Chemotaxis is assayed using a Transwell1 Chamber with a 5 μm-pore size polycarbonate filter. Briefly, cells are incubated for 2 hours in the presence of 1 nM CCL2 and/or 1 μM Cenicriviroc (dissolved in dimethyl sulfoxide with 0.5% acetic acid and diluted 1:1000 with serum-free Roswell Park Memorial Institute-1640 medium and 0.5% bovine serum albumin). Cells are harvested from the lower compartment and analyzed by flow cytometry to enumerate F4/80+CD11b+ macrophages using a 3-laser BD FACSCanto. Results are analyzed using FlowJo software.
  • 動物實(shí)驗(yàn): Animal Models: 8–10 weeks old male C57BL/6 mice, 10–12 weeks old male Sprague-Dawley rats Dosages: 5 mg/kg, 20 mg/kg, 100 mg/kg, 30 mg/kg Administration: Oral gavage, IP
  • 參考文獻(xiàn):
    1. Jacob Lalezari, et al. J Acquir Immune Defic Syndr. 2011 Jun 1;57(2):118-25. 2. Eric Lefebvre, et al. PLoS One. 2016 Jun 27;11(6):e0158
  • 溶解性: Soluble  in  DMSO、Ethanol
  • 保存條件: 2-8℃
  • 配置溶液濃度參考:
    1mg 5mg 10mg
    1 mM 1.435 ml 7.174 ml 14.348 ml
    5 mM 0.287 ml 1.435 ml 2.87 ml
    10 mM 0.143 ml 0.717 ml 1.435 ml
    50 mM 0.029 ml 0.143 ml 0.287 ml
  • 注意:部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權(quán)威性,僅供客戶參考交流研究之用。
輸入產(chǎn)品批號:

本計算器可幫助您計算出特定溶液中溶質(zhì)的質(zhì)量、溶液濃度和體積之間的關(guān)系,公式為:


質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)


  • =
    *
    *


源葉所有產(chǎn)品僅用作科學(xué)研究,銷售產(chǎn)品行為均適用于我司網(wǎng)上所列通用銷售條款。